# Bimekizumab for recalcitrant pyoderma gangrenosum

**Authors:** Christina Tolete, Adam Friedman, Joaquin Calderon, Leonardo Tjahjono

PMC · DOI: 10.1016/j.jdcr.2025.12.018 · JAAD Case Reports · 2026-01-30

## Full-text entities

- **Genes:** IL17F (interleukin 17F) [NCBI Gene 112744] {aka CANDF6, IL-17F, ML-1, ML1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL23A (interleukin 23 subunit alpha) [NCBI Gene 51561] {aka IL-23, IL-23A, IL23P19, P19, SGRF}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}
- **Diseases:** inflammatory bowel disease (MESH:D015212), autoimmune disease (MESH:D001327), hypercholesterolemia (MESH:D006937), PG (MESH:D017511), psoriasis (MESH:D011565), erythema (MESH:D004890), neutrophilic dermatosis (MESH:D016463), HS (MESH:D017497), arterial insufficiency (MESH:D014715), hypertension (MESH:D006973), hematologic dyscrasia (MESH:D006402), lower extremity pain (MESH:D010146), inflammation (MESH:D007249), vasculitis (MESH:D014657), dermatologic and inflammatory diseases (MESH:D000168), ulcer (MESH:D014456), infection (MESH:D007239), Crohn's disease (MESH:D003424), malignancy (MESH:D009369)
- **Chemicals:** Bimekizumab (MESH:C000625981), Prednisone (MESH:D011241), brodalumab (MESH:C571216), adalimumab (MESH:D000068879), methotrexate (MESH:D008727), secukinumab (MESH:C555450), dapsone (MESH:D003622), infliximab (MESH:D000069285), cyclosporine (MESH:D016572), interleukin (IL)-1 inhibitors (-), mycophenolate mofetil (MESH:D009173), Ixekizumab (MESH:C549079)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12963896/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12963896/full.md

## References

17 references — full list in the complete paper: https://tomesphere.com/paper/PMC12963896/full.md

---
Source: https://tomesphere.com/paper/PMC12963896